Predicting response to radiotherapy of intracranial metastases with hyperpolarized 13 C MRI.

Stereotactic radiosurgery (SRS) is used to manage intracranial metastases in a significant fraction of patients. Local progression after SRS can often only be detected with increased volume of enhancement on serial MRI scans which may lag true progression by weeks or months.Patients with intracranial metastases (N = 11) were scanned using hyperpolarized 13C MRI prior to treatment with stereotactic radiosurgery (SRS). The status of each lesion was then recorded at six months post-treatment follow-up (or at the time of death).The positive predictive value of 13C-lactate signal, measured pre-treatment, for prediction of progression of intracranial metastases at six months post-treatment with SRS was 0.8 p<0.05, and the AUC from an ROC analysis was 0.77 p<0.05. The distribution of 13C-lactate z-scores was different for intracranial metastases from different primary cancer types (F = 2.46, p=0.1).Hyperpolarized 13C imaging has potential as a method for improving outcomes for patients with intracranial metastases, by identifying patients at high risk of treatment failure with SRS and considering other therapeutic options such as surgery.

Duke Scholars

Author Casey Yesol Lee Radiation Oncology